Post-Menopausal Osteoporosis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Teriparatide reduces fracture risk in women with severe osteoporosis - Healio



Teriparatide reduces fracture risk in women with severe osteoporosis 
Healio
Postmenopausal women with severe osteoporosis may have a lower risk for new vertebral fractures when treated with the anabolic agent teriparatide compared with risedronate, an antiresorptive therapy, study data show. Piet Geusens, MD, PhD, honorary ...

 


Analysts' Recommendations for Amgen in January 2018 - Market Realist



Market Realist
 
Analysts' Recommendations for Amgen in January 2018 
Market Realist
In January 2018, the European Medical Agency (or EMA) accepted the Marketing Authorization Application (or MAA) for Amgen's (AMGN) and UCB's Evenity. Evenity was accepted for the treatment of osteoporosis in postmenopausal women and in men who are at ...

 


Can We Predict the Risk of Fractures in Women with Postmenopausal Osteoporosis? - Medical News Bulletin



Medical News Bulletin
 
Can We Predict the Risk of Fractures in Women with Postmenopausal Osteoporosis? 
Medical News Bulletin
Increased bone fragility due to deterioration of bone tissue and loss of bone mass, the hallmark characteristics of osteoporosis, can occur for many years without any symptoms showing. Typically, diagnosis occurs after an osteoporotic fracture occurs ...

 


Post Menopausal Osteoporosis ? Global API Manufacturers ... - satPRnews (press release)



Post Menopausal Osteoporosis ? Global API Manufacturers ... 
satPRnews (press release)
The Post Menopausal Osteoporosis ? Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Therapeutic Area, Women's ...

and more » 


Drug combo cuts fracture risk for women with osteoporosis - Futurity: Research News



Futurity: Research News
 
Drug combo cuts fracture risk for women with osteoporosis 
Futurity: Research News
... women and men, though post-menopausal women are particularly susceptible. The progressive loss of bone mass puts those with the condition at greater risk for fracture. To date, there is no effective treatment or cure, which is why the promise of ...

and more » 


European Medicines Agency Accepts Filing For EVENITY? (Romosozumab) - Markets Insider



PharmaTimes
 
European Medicines Agency Accepts Filing For EVENITY? (Romosozumab) 
Markets Insider
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY ...
Amgen Announces Acceptance of MAA for Evenity in Europe - Nasdaq Nasdaq
UCB, Amgen's Evenity under review in Europe - PharmaTimes PharmaTimes

all 6 news articles » 


Hip fractures on the rise in older U.S. women - Reuters - Reuters



Hip fractures on the rise in older U.S. women - Reuters 
Reuters
By Cheryl Platzman Weinstock(Reuters Health) - The incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients.Hip fracture rates declined each year from ...

and more » 


European Medicines Agency Accepts Filing For Amgen's EVENITY - Drug Discovery & Development



Drug Discovery & Development
 
European Medicines Agency Accepts Filing For Amgen's EVENITY 
Drug Discovery & Development
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY (romosozumab) for the treatment of osteoporosis in postmenopausal women ...

 


Radius Health (NASDAQ:RDUS) Rating Increased to Hold at Zacks ... - The Ledger Gazette



Wolcott Daily
 
Radius Health (NASDAQ:RDUS) Rating Increased to Hold at Zacks ... 
The Ledger Gazette
Radius Health (NASDAQ:RDUS) was upgraded by Zacks Investment Research from a ?sell? rating to a ?hold? rating in a research note issued on Monday, January 8th. According to Zacks, ?Radius received a major boost with the approval of Tymlos for the ...
Comparing Zymeworks (ZYME) & Radius Health (NASDAQ:RDUS) Dispatch Tribunal
Radius Health (RDUS) Stock Rating Lowered by Zacks Investment Research Week Herald
Radius Health, Inc. (RDUS) Reaches $35.89 After 6.00% Up Move ... UtahHerald.com
TrueBlueTribune  -Wolcott Daily  -The Lincolnian Online  -Zacks Investment Research 
all 25 news articles » 


Post Menopausal Osteoporosis Market by Key Players, Product and Production Information analysis and forecast to 2025 - satPRnews (press release)



Post Menopausal Osteoporosis Market by Key Players, Product and Production Information analysis and forecast to 2025 
satPRnews (press release)
Segment level epidemiology and market split for Post Menopausal Osteoporosis. The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Post Menopausal Osteoporosis. The Report also covers the market ...

and more »